| U.S. Market Potential - Addressing A $400Bn Substance Abuse Problem(1)
Drug Screening Products Market Segment Size: $14.9Bn by 2030(2)
CAGR: 12.1%(2)
Key Drivers
- Stringent regulations and a focus on workplace safety
- Growth in substance abuse cases
- Demand for faster, non-invasive testing technologies
Opp. for Fingerprint-Based Solutions
- Aligns with market demand for convenience, speed, and accuracy
- Poised to disrupt traditional urine and saliva testing methods
Grab Sources And More: INBS Website. INBS Presentation. -----
And based on multiple potential catalysts mentioned above, (Nasdaq: INBS) has quickly risen the ranks to the top spot on my watchlist. Check them out:
#1. INBS Potential Catalyst - A Low Float Could Create Heightened Volatility In A Flash.
According to info from the Yahoo Finance website, INBS has a fairly low float.
In fact, the website reports this profile to have approx. 8.22Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If the company provides positive news towards the end of 2025, could it, with the help of a low float, help create a breakout spark? -----
#2. INBS Potential Catalyst - Key Oversold Leaning Technicals Suggest A Healthy Reversal/Bounce Could Be Approaching.
At 4:00PM EST Monday, Barchart was reporting INBS to have several oversold leaning technical indicators.
These technicals could be signaling a healthy reversal is approaching in the near term.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
Here's the technicals to pay close attention to (as of 4:00PM EST Monday):
- 9-Day Relative Strength Index: 34.15%
- 14-Day Relative Strength Index: 35.61%
When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.
- 14-Day Raw Stochastic %D: 9.27%
As the Raw Stochastic nears the 10% range and lower it may also be viewed as oversold and undervalued.
Keep an eye on these technicals closely. -----
#3. INBS Potential Catalyst - An Analyst $12 Target Suggests Quadruple-Digit Potential Upside.
From its closing valuation on Monday, that $12 target is suggesting INBS to have over 1,100% potential upside.
This price target reflects strong analyst confidence in Intelligent Bio Solutions Inc.'s future performance, driven by major advances in FDA regulatory pathways for its drug screening system and a strategic expansion into new markets including key partnerships in Europe and initiatives for a U.S. launch.
Ladenburg Thalmann's established reputation as a Wall Street firm adds further weight to the target and underscores the attention INBS could receive as an undervalued profile. -----
#4. INBS Potential Catalyst - The Number Of New Customer Accounts Explodes (Represents 50% Increase Y-O-Y In Q1).
Intelligent Bio Solutions Secures 33 New Customer Accounts in the Fiscal 2026 First Quarter, Showing Strong Year-Over-Year Growth and Increasing Total Active Accounts to 480
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), ..., today announced the addition of 33 new customer accounts during its fiscal first quarter for the period ended September 30, 2025, representing a 50% increase compared with the same period the prior year. The continued growth brings the Company’s total number of active accounts to over 480, demonstrating sustained customer expansion and revenue momentum.
Year-over-year analysis, based on full-year figures, highlights the strongest growth in customer acquisition within the maritime, transportation and logistics, electrical and electronic manufacturing, construction, and government administration sectors. Notably, government administration represents a newly entered sector, emphasizing the expanding applicability of INBS's solutions across both public and private domains where operational safety and compliance are critical.
"Our expanding customer base demonstrates increasing confidence in our technology and the growing recognition of its value proposition. As we move toward the second quarter of fiscal year 2026, our focus remains on converting this momentum into sustained revenue growth and long-term value," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "Our fingerprint-based drug testing technology is helping organizations streamline screening, minimize downtime, and enhance compliance, delivering measurable operational and economic benefits."
Growth was particularly strong in the United Kingdom, supported by expanding distributor activity across Europe and the Middle East. Approximately 91% of new accounts were first-time adopters of INBS's drug screening solution, while the remaining 9% represented expansion within existing customer organizations, highlighting the Company's ability to attract new users and deepen engagement among its established customer base.
"Adoption is broadening across new and existing customers," said Doug Heath, Vice President of Global Sales at Intelligent Bio Solutions. “More industries are recognizing the operational value of our solution, and existing customers are scaling use as confidence in its accuracy and reliability strengthens."
...
Read the full article here. -----
#5. INBS Potential Catalyst - FDA 510(k) Submission Anticipated In 2nd Half Of 2026 (Updated Timeline).
Intelligent Bio Solutions Advances Preparations and Provides Updated Timeline for Anticipated FDA 510(k) Submission and Clearance
The Company is initiating clinical studies to further validate Intelligent Fingerprinting Drug Screening System
INBS anticipates FDA 510(k) clearance in the second half of 2026
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), ..., today is providing an update on the timeline for anticipated FDA 510(k) clearance for the use of its Intelligent Fingerprinting Drug Screening System for the o-piate co-deine.
Following recent feedback from the U.S. Food and Drug Administration (FDA), INBS has established a pathway to gather additional supporting data to strengthen its new 510(k) submission to the FDA. The Company plans to commence clinical studies to further validate its Intelligent Fingerprinting Drug Screening System before calendar year-end. These studies are scheduled to conclude in the first half of the 2026 calendar year. INBS anticipates FDA 510(k) clearance in the second half of the 2026 calendar year.
“We have a clear and achievable timeline for resubmitting our 510(k) application. The additional clinical data we are generating will supplement existing data and strengthen our package,” said Peter Passaris, Vice President of Product Development at Intelligent Bio Solutions. “We are committed to bringing our innovative technology to the U.S. market, while continuing to focus on the growth of the overall business.”
...
Read the full article here. -----
(Nasdaq: INBS) Recap - 5 Potential Catalysts Lead The Way
#1. A Low Float Could Create Heightened Volatility In A Flash.
#2. Key Oversold Leaning Technicals Suggest A Healthy Reversal/Bounce Could Be Approaching.
#3. An Analyst $12 Target Suggests Quadruple-Digit Potential Upside.
#4. The Number Of New Customer Accounts Explodes (Represents 50% Increase Y-O-Y In Q1).
#5. FDA 510(k) Submission Anticipated In 2nd Half Of 2026 (Updated Timeline). -----
We're now reinitiating coverage on Intelligent Bio Solutions Inc. (Nasdaq: INBS).
As soon as updates pop up, I'll get them out quickly. Talk soon.
Sincerely, Kai Parker StockWireNews
Sources: (1)(2)
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 11/04/2025 and ending on 11/04/2025 to publicly disseminate information about (INBS:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid forty two thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (INBS:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/inbs-uvidh/#details | 
0 التعليقات:
إرسال تعليق